Homocysteine
For informational purposes only — not medical advice. Always consult a qualified healthcare provider before making changes to your health regimen. Full disclaimer →
- Elevated homocysteine is an independent cardiovascular and cognitive risk factor — associated with higher rates of heart attack, stroke, dementia, and all-cause mortality across dozens of large prospective studies. Most people have never had it tested.
- Longevity-optimal target: below 7 µmol/L. Standard labs call anything below 15 µmol/L normal. But risk is continuous — even levels of 10–12 µmol/L carry meaningfully higher cardiovascular and cognitive risk than levels below 7.
- Elevated homocysteine is highly correctable. In the majority of cases, levels can be normalized with folate, vitamin B12, and vitamin B6 supplementation — often within 4–8 weeks. This makes it one of the most actionable longevity markers.
- MTHFR variants matter. A common genetic variant in the MTHFR gene impairs folate metabolism and is one of the most common genetic contributors to elevated homocysteine. People with MTHFR variants may need methylated forms of folate (5-MTHF) and B12 (methylcobalamin) rather than standard supplements.
- Homocysteine is a direct marker of methylation status. The methylation cycle governs DNA repair, neurotransmitter synthesis, and epigenetic regulation. Elevated homocysteine signals methylation dysfunction — with implications far beyond just cardiovascular risk.
The Overlooked Amino Acid That Ages Your Brain and Heart
Homocysteine occupies a peculiar position in medicine: the evidence linking it to cardiovascular disease and dementia is extensive and well-established, yet it remains one of the least-ordered markers in standard clinical care. Most adults have never had it tested. Many physicians do not routinely include it even in comprehensive cardiovascular workups. This gap between evidence and practice has real consequences — because elevated homocysteine is not just a risk marker. It is one of the most correctable ones.
The story of homocysteine and cardiovascular disease begins with a physician named Kilmer McCully, who in the late 1960s proposed — based on autopsy findings in children with rare disorders of homocysteine metabolism — that homocysteine caused atherosclerosis independently of cholesterol. His hypothesis was rejected at the time and he lost his position at Harvard Medical School. Decades later, large prospective studies in general populations confirmed the relationship, and McCully's insight was vindicated. Elevated homocysteine is now recognized as an independent predictor of cardiovascular events, stroke, and cognitive decline.
A meta-analysis by Homocysteine Studies Collaboration published in the Journal of the American Medical Association pooled data from 30 prospective studies and found that each 5 µmol/L increase in homocysteine was associated with a 32% increase in ischemic heart disease risk in men and a 29% increase in women — after adjustment for conventional cardiovascular risk factors. 1
The practical upshot: homocysteine belongs in every longevity biomarker panel, and it deserves particular attention because it can almost always be meaningfully improved.
Standard Reference Ranges vs. Longevity-Optimal Ranges
Standard clinical reference ranges for homocysteine define elevated as above 15 µmol/L, with some labs using slightly different cutoffs. This threshold was derived primarily from studies of cardiovascular endpoints in populations with established disease, and it represents a relatively conservative definition of "high risk" — not an optimization target.
| Category | Homocysteine Level | Standard Interpretation | Longevity Assessment |
|---|---|---|---|
| Longevity-optimal | Below 7 µmol/L | Normal / low | Optimal — minimal vascular and cognitive risk |
| Good | 7–9 µmol/L | Normal | Good — monitor; optimize B-vitamin status |
| Monitor | 9–12 µmol/L | Normal | Monitor — below optimal; B-vitamin optimization indicated |
| Elevated | 12–15 µmol/L | Borderline / high-normal | Elevated — intervention needed; assess B12, folate, MTHFR |
| High | Above 15 µmol/L | Elevated (clinical) | High — significant risk; active treatment required |
What makes the longevity-optimal cutoff of 7 µmol/L important is the research showing that risk is continuous across the range. A person at 12 µmol/L is not "fine" just because they are below the clinical threshold of 15. Multiple large studies demonstrate that risk increases meaningfully at levels well within the "normal" clinical range.
Already have your lab results? See how your Homocysteine and other markers score on a longevity scale — in under 60 seconds.
Analyze My Biomarkers →How Homocysteine Damages the Body
Homocysteine is not inert at elevated levels — it is chemically reactive and toxic to several tissue types through multiple mechanisms:
- Endothelial damage: Homocysteine directly injures the endothelium — the single-cell layer lining blood vessels. It promotes oxidative stress within endothelial cells, impairs nitric oxide production (which normally relaxes blood vessels and inhibits clot formation), and activates inflammatory pathways. This creates a pro-atherosclerotic environment independently of LDL cholesterol. This is why homocysteine predicts cardiovascular events even in people with otherwise normal lipid profiles.
- Prothrombotic effects: Homocysteine activates both platelet aggregation and coagulation factors, increasing the tendency to form blood clots. This explains its strong association with venous thromboembolism (deep vein thrombosis and pulmonary embolism) as well as arterial events like heart attack and stroke.
- Brain atrophy: The brain is particularly vulnerable to homocysteine's effects. Elevated levels are associated with accelerated brain atrophy, particularly in regions critical to memory and executive function. The landmark VITACOG trial demonstrated that B-vitamin supplementation in people with elevated homocysteine and mild cognitive impairment reduced brain atrophy by 53% over two years — one of the most striking intervention findings in cognitive aging research. 2
- Methylation disruption: Elevated homocysteine signals impairment of the methylation cycle — one of the body's most fundamental biochemical processes. Methylation governs DNA synthesis and repair, gene expression regulation (epigenetics), neurotransmitter synthesis (including dopamine and serotonin), and detoxification. When the methylation cycle is dysregulated, the downstream consequences extend far beyond homocysteine itself.
- Bone effects: Homocysteine impairs collagen cross-linking in bone matrix, contributing to reduced bone quality and increased fracture risk — independent of bone mineral density.
The Methylation Cycle — Why Homocysteine Is a Window Into Deeper Biology
To understand homocysteine fully, it helps to understand the biochemical cycle it belongs to. Homocysteine sits at a critical junction in methionine metabolism, and what happens to it depends on the efficiency of two pathways:
The methylation (remethylation) pathway converts homocysteine back to methionine using a methyl group donated by 5-methyltetrahydrofolate (5-MTHF) — the active form of folate — with vitamin B12 as a cofactor. This is the primary route and the one most commonly impaired by nutritional deficiency or MTHFR variants. Methionine produced by this cycle is then used to make SAM (S-adenosylmethionine), the body's universal methyl donor for hundreds of methylation reactions throughout the body.
The transsulfuration pathway converts homocysteine irreversibly to cysteine, using vitamin B6 as a cofactor. This pathway provides cysteine for glutathione synthesis — the body's primary antioxidant. When B6 is deficient or the methylation pathway is overwhelmed, flux through transsulfuration is reduced, impairing glutathione production.
When either pathway is impaired, homocysteine accumulates. A blood homocysteine level above optimal is therefore not just a cardiovascular risk marker — it is a signal that the methylation cycle is underperforming, with downstream effects on DNA methylation, neurotransmitter production, and antioxidant capacity. This is why homocysteine is increasingly recognized as a marker of methylation status and overall cellular repair capacity, and why longevity-focused practitioners treat it as a priority.
What Drives Homocysteine Up — and Down
Factors that raise homocysteine
- Folate deficiency — the most common nutritional driver; folate is the primary methyl donor for homocysteine remethylation; low intake or impaired absorption consistently raises levels
- Vitamin B12 deficiency — required as a cofactor in the methylation cycle; deficiency is common in older adults, vegetarians, and those taking metformin or proton pump inhibitors long-term
- Vitamin B6 deficiency — required for the transsulfuration pathway; deficiency shifts homocysteine toward accumulation
- MTHFR gene variants — particularly C677T; impairs conversion of folate to its active form; extremely common (10–15% of the population is homozygous)
- Renal insufficiency — the kidneys play an important role in homocysteine clearance; even modest reductions in eGFR raise levels
- Hypothyroidism — slows homocysteine metabolism; normalizes with thyroid treatment
- Age — homocysteine tends to rise with age, partly due to declining B12 absorption and renal function
- Male sex — men tend to have higher homocysteine than women of the same age, for reasons not fully understood
- Excess alcohol — impairs folate absorption and increases folate excretion
- Excess coffee — associated with modestly elevated homocysteine, possibly via effects on B-vitamin metabolism
- Certain medications — methotrexate (folate antagonist), phenytoin and other anticonvulsants, metformin (B12 depletion), proton pump inhibitors (B12 absorption), niacin (at high doses)
Factors that lower homocysteine
- Folate (as methylfolate / 5-MTHF) - the most reliable intervention; dietary folate from leafy greens, legumes, and fortified foodor, or supplemental 5-MTHF (400–800 µg/day) for those with MTHFR variants
- Vitamin B12 (methylcobalamin or hydroxocobalamin) — particularly important for older adults and vegetarians; sublingual or injectable forms bypass absorption issues
- Vitamin B6 (pyridoxine or pyridoxal-5-phosphate) — supports the transsulfuration pathway; the active form P5P is better absorbed in some individuals
- Riboflavin (vitamin B2) — an often-overlooked cofactor; riboflavin is required for MTHFR enzyme activity, and supplementation lowers homocysteine specifically in people with the MTHFR C677T variant
- Betaine (trimethylglycine) — provides an alternative methyl group for homocysteine remethylation independent of folate; used as an adjunct when B-vitamin response is incomplete
- Reducing alcohol intake — even moderate reductions improve homocysteine through better folate status
- Treating hypothyroidism — improving thyroid function improves homocysteine metabolism
- Treating renal disease — improving GFR reduces homocysteine accumulation
MTHFR — Why Standard Folic Acid May Not Be Enough
The MTHFR C677T polymorphism is one of the most clinically relevant common genetic variants in longevity medicine — and one of the most misunderstood. People with two copies of the variant (homozygous C677T, approximately 10–15% of the population) have MTHFR enzyme activity reduced by roughly 60–70%. Their ability to convert dietary folate and folic acid into the active form the methylation cycle requires (5-MTHF) is substantially impaired.
The practical consequence: for homozygous MTHFR individuals, supplementing with standard folic acid may provide little benefit for homocysteine. Folic acid requires conversion by MTHFR to become active — and that conversion is precisely what is impaired. The effective intervention is to supplement with 5-MTHF (methylated folate) directly, along with methylcobalamin (methyl-B12), bypassing the impaired enzyme entirely.
Riboflavin (vitamin B2) also plays a specific and underappreciated role here: MTHFR requires riboflavin as a cofactor, and riboflavin supplementation has been shown in randomized trials to lower homocysteine specifically in people with the C677T variant, even without additional folate.
Knowing your MTHFR status — available through standard genetic testing — allows for more targeted supplementation. But the practical approach for anyone with persistently elevated homocysteine that does not respond adequately to standard B-vitamin supplementation is to simply switch to methylated forms, regardless of whether genetic testing has been done.
How to Test Homocysteine
Homocysteine is measured from a standard fasting blood draw. Fasting is important — levels rise transiently after protein-containing meals. Some labs also require that samples be processed quickly, as red blood cells continue to produce homocysteine in the test tube after collection; delayed processing can artificially elevate results. Reputable commercial labs handle this correctly, but it is worth noting if results seem unexpectedly high.
The test measures total plasma homocysteine — the sum of free and protein-bound forms. This is the clinically relevant measurement for cardiovascular and cognitive risk assessment.
Through a longevity testing service: InsideTracker includes homocysteine in their comprehensive panel alongside B-vitamin markers, cardiovascular lipids, and metabolic markers — providing the most useful context for interpreting results and identifying the likely cause of elevation.
À la carte through Ulta Lab Tests: Homocysteine can be ordered without a doctor's visit for approximately $30–40, with results in 24–48 hours. This is a practical option for initial testing or for monitoring after starting B-vitamin supplementation.
Through your physician: Homocysteine can be ordered by any primary care physician. It is typically included in cardiovascular risk panels but is often not part of standard annual bloodwork — request it specifically.
How Often Should You Test?
If your homocysteine is in the optimal range (below 7 µmol/L) and your B-vitamin status is good, testing every 12 months as part of a comprehensive panel is sufficient.
If your homocysteine is elevated and you are starting B-vitamin supplementation, retest after 8–12 weeks to assess response. Homocysteine responds relatively quickly to supplementation — levels typically begin falling within 2–4 weeks of correcting a B-vitamin deficiency, and most of the achievable reduction occurs within 8–12 weeks. If levels remain elevated despite supplementation, consider: switching to methylated forms (5-MTHF and methylcobalamin), checking B12 and folate levels directly, testing for renal function, and assessing thyroid status.
Always interpret homocysteine alongside ApoB and hsCRP for a complete cardiovascular risk picture — these three markers capture complementary and largely non-overlapping risk pathways.
Sources
- Homocysteine Studies Collaboration. "Homocysteine and Risk of Ischemic Heart Disease and Stroke." JAMA, 2002. PubMed →
- Smith AD, et al. "Homocysteine-Lowering by B Vitamins Slows the Rate of Accelerated Brain Atrophy in Mild Cognitive Impairment: A Randomized Controlled Trial." PLOS ONE, 2010. PubMed →
- McNulty H, et al. "Riboflavin Lowers Homocysteine in Individuals Homozygous for the MTHFR 677C→T Polymorphism." Circulation, 2006. PubMed →
| Range Type | Value (µmol/L) | Notes |
|---|---|---|
| Standard Clinical Range | Below 15 µmol/L | Designed to identify disease risk — not longevity optimisation. |
| Longevity-Optimal Target | Below 7 µmol/L |
Associated with reduced all-cause mortality and extended healthspan.
Standard labs flag homocysteine as elevated at above 15 µmol/L. Longevity medicine targets below 7 µmol/L — based on research showing a continuous, dose-dependent relationship between homocysteine and cardiovascular and cognitive risk well within the 'normal' range. The VITATOPS, HOPE-2, and Oxford B-vitamin trials all suggest benefit from homocysteine lowering, and epidemiological data indicate the lowest risk at levels below 7–8 µmol/L.
|
Already have your results? See what your Homocysteine and other markers reveal about your longevity in 60 seconds.
Analyze My Labs →Affiliate disclosure: we may earn a commission if you purchase through these links at no extra cost to you.
What is a good homocysteine level for longevity?
For longevity optimization, the target homocysteine is below 7 µmol/L. Standard clinical reference ranges flag anything above 15 µmol/L as elevated, but research consistently shows that cardiovascular and cognitive risk increases continuously across a much wider range — even levels between 10–14 µmol/L are associated with meaningfully worse outcomes than levels below 7. The relationship is not a threshold effect; it is a gradient, and lower is better within the physiologically normal range.
What causes elevated homocysteine?
The most common causes are nutritional deficiencies — particularly folate, vitamin B12, and vitamin B6, all of which are required for homocysteine metabolism. Other contributors include: the MTHFR gene variant (which impairs folate conversion), renal insufficiency (the kidneys help clear homocysteine), hypothyroidism, certain medications (methotrexate, phenytoin, proton pump inhibitors), older age, male sex, and excess alcohol or coffee intake. In many people, multiple factors combine.
What is the MTHFR gene and does it affect homocysteine?
MTHFR (methylenetetrahydrofolate reductase) is an enzyme required to convert dietary folate into its active form (5-methyltetrahydrofolate, or 5-MTHF), which is then used in the methylation cycle to recycle homocysteine. Common MTHFR variants — particularly C677T, found in approximately 10–15% of the population in homozygous form — reduce this enzyme's activity by 60–70%, impairing homocysteine clearance. People with MTHFR variants often respond poorly to folic acid (the synthetic form in most supplements and fortified foods) and benefit from methylated folate (5-MTHF) and methylcobalamin (methyl-B12) instead.
Can homocysteine be lowered with diet and supplements?
Yes — and this is one of the most compelling aspects of homocysteine as a longevity marker. In the majority of cases, elevated levels can be significantly reduced with B-vitamin supplementation. Multiple randomized controlled trials have demonstrated that combinations of folic acid (or methylated folate), vitamin B12, and vitamin B6 reliably lower homocysteine by 20–30% or more. Dietary improvements — increasing leafy greens, legumes, and fortified foods — also help, as does reducing alcohol and coffee intake. For people with the MTHFR variant, using methylated forms of folate and B12 is important for optimal response.
Does lowering homocysteine reduce disease risk?
The evidence here is nuanced. Epidemiological data consistently show that lower homocysteine is associated with better cardiovascular and cognitive outcomes. Randomized trials of B-vitamin supplementation have shown mixed results on hard cardiovascular endpoints — likely because most trials enrolled people who already had established disease or elevated baseline risk factors that couldn't be fully reversed. However, the VITACOG trial showed that B-vitamin supplementation dramatically slowed brain atrophy in people with elevated homocysteine and mild cognitive impairment — a compelling finding for cognitive longevity. The current longevity medicine consensus is that normalizing elevated homocysteine is worthwhile, particularly given the low risk and high tolerability of B-vitamin supplementation.